These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7039813)

  • 1. Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.
    Omura GA; Vogler WR; Lefante J; Silberman H; Knospe W; Gordon D; Jarrell R
    Cancer; 1982 Apr; 49(8):1530-6. PubMed ID: 7039813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens.
    Presant CA; Berger NA; Klahr C; Phillips GL
    Cancer; 1980 Jul; 46(1):22-8. PubMed ID: 6930320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonging remission in myeloblastic leukemia by tice-strain bacillus Calmette-Guérin.
    Vogler WR; Chan YK
    Lancet; 1974 Jul; 2(7873):128-31. PubMed ID: 4135502
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.
    Vogler WR; Winton EF; Gordon DS; Raney MR; Go B; Meyer L
    Blood; 1984 May; 63(5):1039-45. PubMed ID: 6201211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive chemotherapy for acute myelogenous leukemia.
    Gale RP; Foon KA; Cline MJ; Zighelboim J
    Ann Intern Med; 1981 Jun; 94(6):753-7. PubMed ID: 6940466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
    Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.
    Mandelli F; De Lipsis E; Grignani F; Martelli M; Liso V; Amadori S
    Med Pediatr Oncol; 1978; 4(3):231-40. PubMed ID: 277749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
    J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
    Sartiano GP; Pfrimmer WJ; Turner AR
    Med Pediatr Oncol; 1978; 4(3):205-12. PubMed ID: 277748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of 100 acute myeloid leukemias (author's transl)].
    Fière D; Martin C; Vu Van H; Coiffier B; Felman P; Bryon PA; Favre-Gilly J; Revol L
    Sem Hop; 1979 Apr 8-15; 55(13-14):633-8. PubMed ID: 224478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in acute myelogenous leukemia.
    Gale RP
    Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High rate of long-term survival in adult acute leukemia following ten-day chemotherapy (OAP) induction. Maintenance with chemotherapy or chemotherapy plus BCG vaccine.
    Hewlett JS; Chen T; Balcerzak SP; Gutterman JU; Costanzi JJ; Amare M
    Arch Intern Med; 1985 Jun; 145(6):1006-12. PubMed ID: 3890786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
    Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
    Zuhrie SR; Harris R; Freeman CB; MacIver JE; Geary CG; Delamore IW; Tooth JA
    Br J Cancer; 1980 Mar; 41(3):372-7. PubMed ID: 6992827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuraminidase-treated allogeneic blasts for maintenance in acute myelogenous leukemia: results of a prospective randomized trial.
    Urbanitz D; Büchner T; Pielken H; Koch P; Ludwig WD; Maschmeier G; Heinecke A; van de Loo J
    Haematol Blood Transfus; 1987; 30():64-8. PubMed ID: 3305224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
    Jehn U; Knüppel W; Wilmanns W
    Onkologie; 1988 Feb; 11(1):13-7. PubMed ID: 3283620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.